Published in the journal JAMA Internal Medicine. Here is a link to the article.
Regenstrief Institute authors: Tom Imperiale, M.D.
This editorial examines whether the multitarget stool DNA (mt-sDNA) test is truly more effective than fecal immunochemical tests (FIT) for colorectal cancer screening or just more complex and costly. While lowering the FIT threshold can improve sensitivity, mt-sDNA still outperforms FIT even at comparable specificity levels. Differences in study methods—such as comparing separate cohorts or using different FIT brands—may explain conflicting results. The authors emphasize the need for direct, same-sample comparisons to accurately assess test performance.
Authors
Thomas F. Imperiale, M.D.1,2,3,4
Author Affiliations
1Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis
2Center for Health Information Communication, Health Services Research and Development, the Richard L. Roudebush VA Medical Center, Indianapolis, Indiana
3Regenstrief Institute, Inc, Indianapolis, Indiana
4Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana
